These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9491207)

  • 21. Intracellular calcium changes associated with in vitro lymphokine-activated killer and natural killer cell cytotoxicity.
    Burkey BB; Omann GM; Wolf GT
    Arch Otolaryngol Head Neck Surg; 1991 Nov; 117(11):1281-6. PubMed ID: 1747234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients.
    Provinciali M; Di Stefano G; Stronati S; Fabris N
    Cytokine; 1998 Feb; 10(2):132-9. PubMed ID: 9512903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The regulatory effect of adherent cells on lymphokine activated killer cells.
    Ibayashi Y; Hoon DS; Golub SH
    Cell Immunol; 1987 Dec; 110(2):365-78. PubMed ID: 2446780
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of murine lymphokine-activated killer (LAK) cell activity by adherent cells.
    Longley RE; Stewart D; Roe KG; Good RA
    Cell Immunol; 1989 Jul; 121(2):225-36. PubMed ID: 2786756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Generation of human lymphokine-activated killer cells following brief exposure to high dose interleukin 2.
    Horton SA; Oldham RK; Yannelli JR
    Cancer Res; 1990 Mar; 50(6):1686-92. PubMed ID: 2306722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of lymphokine-activated killer cells generation in vitro by soluble factors released from mixed human tumor and peripheral blood mononuclear adherent cells culture.
    Eisenthal A; Barbarsteyn E; Gitstein G; Lifschitz-Mercer B
    Cancer Invest; 2006 Feb; 24(1):28-34. PubMed ID: 16466989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of parameters for maximal in vitro proliferation and activation of lymphokine-activated killer cells (LAK).
    Coze C; Combaret V; Philip I; Négrier S; Colin C; Gaspard M; Franks CR; Bijman JT; Philip T; Favrot M
    Nouv Rev Fr Hematol (1978); 1989; 31(5):339-43. PubMed ID: 2587202
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.
    Atagi S; Sone S; Fukuta K; Ogura T
    Jpn J Cancer Res; 1992 Oct; 83(10):1088-94. PubMed ID: 1452461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon gamma enhances lymphokine-activated killer cell adhesion but not lysis of head and neck squamous cell carcinoma.
    Scher RL; Carras A; Schwab D; Richtsmeier WJ; Koch WM
    Arch Otolaryngol Head Neck Surg; 1995 Nov; 121(11):1271-5. PubMed ID: 7576474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation of murine lymphokine (rIL-2)-activated killer cell activity by indomethacin.
    Chao TY; Ohnishi H; Chu TM
    Mol Biother; 1989; 1(6):318-22. PubMed ID: 2610950
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of lymphotoxin in the IL-2-driven differentiation of human lymphokine-activated T-killer (T-LAK) cells in vitro.
    Abe Y; Van Eden M; Gatanaga M; Wang FI; Brightbill HD; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Oct; 12(5):279-83. PubMed ID: 8260536
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intercellular adhesion molecule-1 expression by bladder cancer cells: functional effects.
    Campbell SC; Tanabe K; Alexander JP; Edinger M; Tubbs RR; Klein EA
    J Urol; 1994 May; 151(5):1385-90. PubMed ID: 7908992
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction by interleukin-7 of lymphokine-activated killer activity in lymphocytes from autologous and syngeneic marrow transplant recipients before and after systemic interleukin-2 therapy.
    Pavletic Z; Benyunes MC; Thompson JA; Lindgren CG; Massumoto C; Alderson MR; Buckner CD; Fefer A
    Exp Hematol; 1993 Sep; 21(10):1371-8. PubMed ID: 8359237
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Substance P increases in vitro lymphokine-activated-killer (LAK) cell cytotoxicity against fresh colorectal cancer cells.
    Flageole H; Senterman M; Trudel JL
    J Surg Res; 1992 Nov; 53(5):445-9. PubMed ID: 1279274
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of IL-2 and IL-2R SNPs on proliferation and tumor- killing activity of lymphokine-activated killer cells from healthy chinese blood donors.
    Li Y; Meng FD; Tian X; Sui CG; Liu YP; Jiang YH
    Asian Pac J Cancer Prev; 2014; 15(18):7965-70. PubMed ID: 25292096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of colony-stimulating factors on cellular cytotoxicity.
    Durek C; Schäfer I; Braasch H; Ulmer AJ; Ernst M; Flad HD; Jocham D; Böhle A
    Cancer Immunol Immunother; 1997 Mar; 44(1):35-40. PubMed ID: 9111582
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Indomethacin up-regulates the generation of lymphokine-activated killer-cell activity and antibody-dependent cellular cytotoxicity mediated by interleukin-2.
    Eisenthal A
    Cancer Immunol Immunother; 1990; 31(6):342-8. PubMed ID: 2386979
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer (NK) and lymphokine-activated killer (LAK) activities in a patient who recovered from cancer, and the characteristics of LAK cells generated from CD4-CD8- and CD8+ peripheral blood lymphocytes.
    Komatsu F; Kihara K
    Clin Immunol Immunopathol; 1995 Oct; 77(1):75-81. PubMed ID: 7554487
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: comparison with effects of Bryostatin 1 on lymphocyte function in vitro.
    Scheid C; Prendiville J; Jayson G; Crowther D; Fox B; Pettit GR; Stern PL
    Cancer Immunol Immunother; 1994 Oct; 39(4):223-30. PubMed ID: 7954524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of enhanced cellular adhesion in IL-6-augmented lymphokine-activated killer-cell function.
    Iho S; Shau H
    Scand J Immunol; 1994 Mar; 39(3):233-40. PubMed ID: 8128185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.